Minoxidil
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Minoxidil: From Androgenetic Alopecia to Hypotrichosis Simplex of the Scalp
One-Sentence Summary
Minoxidil is a vasodilator that was first used as an oral antihypertensive and is now widely used topically for androgenetic alopecia (hair loss). The TxGNN model predicts it may be effective for hypotrichosis simplex of the scalp, a rare hereditary hair-thinning disorder. Evidence is thin: 0 registered clinical trials and 3 publications, all case reports in which minoxidil was combined with other treatments.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Androgenetic alopecia (topical use), based on the literature. The US licence records list no indication text. |
| Predicted New Indication | Hypotrichosis simplex of the scalp |
| TxGNN Prediction Score | 99.9999% |
| Evidence Level | L4 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 20 authorization records (mix of NDA, ANDA and OTC monograph entries) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not available in the DrugBank record. The mechanism below is drawn from the retrieved literature and the evidence review.
Minoxidil is a prodrug. Its sulfate metabolite opens ATP-sensitive potassium (K-ATP) channels. This prolongs the anagen (growth) phase of the hair cycle and increases blood flow around the follicle. Reviews also describe additional pathways, including Wnt/β-catenin signaling and anti-inflammatory effects.
Hypotrichosis simplex of the scalp is a rare, autosomal dominant disorder. Cases have been linked to variants in the CDSN gene, which encodes corneodesmosin. The hair follicles are present but produce sparse hair. A follicle-stimulating drug like minoxidil could plausibly help, and topical minoxidil is already established for the common hair-thinning disorder androgenetic alopecia.
The three case reports do not isolate minoxidil’s own effect. Each one combined it with another therapy: oral minoxidil with growth factors, minoxidil with botanic extracts, or topical minoxidil with platelet-rich plasma (PRP) injections. The high TxGNN score reflects the model’s graph proximity to other hair-loss diseases and is not clinical proof.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 35761391 | 2022 | Case report/series | Dermatologic Therapy | Hereditary hypotrichosis simplex of the scalp treated with oral minoxidil plus growth factors. No abstract is available, so outcome details could not be extracted. |
| 39902296 | 2024 | Case report | Frontiers in Genetics | An 8-year-old boy with CDSN-mutation hypotrichosis simplex of the scalp was treated with botanic extracts plus minoxidil. The paper notes that no definitive, effective treatment exists for this disease. |
| 36651821 | 2023 | Case report | Journal of Dermatological Treatment | A 14-year-old with hereditary hypotrichosis simplex was treated with PRP injections plus topical 2% minoxidil. The title reports successful treatment, but this is a single patient on combination therapy. |
US Market Information
| Authorization Number | Product Name | Dosage Form |
|---|---|---|
| Not listed | 5% Minoxidil Topical Solution | Solution |
| 505G(a)(3) | Hair Growth Foam | Aerosol, foam |
| 505G(a)(3) | Hair Serum | Solution |
| M032 | Psalmonica Hair Growth Serum | Liquid |
| ANDA209074 | Hair Regrowth Treatment | Liquid |
The licence records contain no approved-indication text. The full set of 20 records also includes shampoo and oral tablet forms.
Safety Considerations
Please refer to the package insert for safety information.
Oral minoxidil is a potent systemic vasodilator. It carries known risks of fluid retention, reflex tachycardia and pericardial effusion. This matters here because two of the three case reports used oral minoxidil or involved children.
Conclusion and Next Steps
Decision: Hold
Rationale: The mechanism is plausible and the drug is already marketed for hair loss. However, the only support is three case reports on combination therapy, with no registered trials, so minoxidil’s own contribution cannot be separated out. This is best treated as a research question for now.
To proceed, the following is needed:
- Full-text review of the three case reports to extract dose, route, duration and outcomes
- A small controlled study or case series comparing minoxidil alone with a comparator, in confirmed CDSN-related patients
- The package insert warnings and contraindications, especially for oral use in children
- The mechanism-of-action record from DrugBank
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.